[go: up one dir, main page]

WO2007065289A3 - 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders - Google Patents

4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders Download PDF

Info

Publication number
WO2007065289A3
WO2007065289A3 PCT/CH2006/000689 CH2006000689W WO2007065289A3 WO 2007065289 A3 WO2007065289 A3 WO 2007065289A3 CH 2006000689 W CH2006000689 W CH 2006000689W WO 2007065289 A3 WO2007065289 A3 WO 2007065289A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
tretinoin
topical treatment
iso
dermatological disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CH2006/000689
Other languages
French (fr)
Other versions
WO2007065289A2 (en
Inventor
Pierre Barbier
Jutta Heim
Hoffmann Anne Schmitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica AG
Original Assignee
Basilea Pharmaceutica AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica AG filed Critical Basilea Pharmaceutica AG
Priority to EP06817741A priority Critical patent/EP1971331A2/en
Priority to JP2008543631A priority patent/JP5112328B2/en
Publication of WO2007065289A2 publication Critical patent/WO2007065289A2/en
Publication of WO2007065289A3 publication Critical patent/WO2007065289A3/en
Priority to US12/132,998 priority patent/US20090149536A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of a compound selected from 4-oxo-tretinoin, 4-oxo-isotretinoin and mixtures thereof for the manufacture of a medicament for topically inhibiting the lipogenesis in the skin and/or reducing the sebaceous gland size of a patient in need thereof and/or for the topical treatment of severe acne and seborrhoea.
PCT/CH2006/000689 2005-12-09 2006-12-08 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders Ceased WO2007065289A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06817741A EP1971331A2 (en) 2005-12-09 2006-12-08 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
JP2008543631A JP5112328B2 (en) 2005-12-09 2006-12-08 4-Oxo (iso) tretinoin for topical treatment of severe dermatological disorders
US12/132,998 US20090149536A1 (en) 2005-12-09 2008-06-04 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05026949.7 2005-12-09
EP05026949 2005-12-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/132,998 Continuation-In-Part US20090149536A1 (en) 2005-12-09 2008-06-04 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders

Publications (2)

Publication Number Publication Date
WO2007065289A2 WO2007065289A2 (en) 2007-06-14
WO2007065289A3 true WO2007065289A3 (en) 2007-08-02

Family

ID=38009772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2006/000689 Ceased WO2007065289A2 (en) 2005-12-09 2006-12-08 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders

Country Status (4)

Country Link
US (1) US20090149536A1 (en)
EP (1) EP1971331A2 (en)
JP (1) JP5112328B2 (en)
WO (1) WO2007065289A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130862T1 (en) 2009-09-21 2013-10-25 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SI2595980T1 (en) 2010-07-22 2014-11-28 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
TWI740546B (en) 2014-10-29 2021-09-21 美商基利科學股份有限公司 Methods for the preparation of ribosides
LT3785717T (en) 2015-09-16 2022-04-11 Gilead Sciences, Inc. TREATMENTS FOR CORONAVIRIDAE INFECTIONS
MX395001B (en) * 2017-03-08 2025-03-24 Centro Int De Cosmiatria S A P I De C V COMPOSITION AND METHOD FOR THE TOPICAL TREATMENT OF SEVERE ACNE.
CN110869028B (en) 2017-03-14 2023-01-20 吉利德科学公司 Method of treating feline coronavirus infection
CA3178212A1 (en) 2017-05-01 2018-11-08 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
PE20230618A1 (en) 2020-06-24 2023-04-14 Gilead Sciences Inc 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF
DK4204421T3 (en) 2020-08-27 2024-05-27 Gilead Sciences Inc Compounds and methods for treating viral infections
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169103A (en) * 1978-04-12 1979-09-25 Hoffmann-La Roche Inc. Nonatetraenoic acid derivatives
GB2156676A (en) * 1984-04-02 1985-10-16 Hoffmann La Roche Pharmaceutical preparations containing vitamin A derivatives
US5698593A (en) * 1988-04-26 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Method for treating acne
WO2005011667A1 (en) * 2003-07-30 2005-02-10 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoid components

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169103A (en) * 1978-04-12 1979-09-25 Hoffmann-La Roche Inc. Nonatetraenoic acid derivatives
GB2156676A (en) * 1984-04-02 1985-10-16 Hoffmann La Roche Pharmaceutical preparations containing vitamin A derivatives
US5698593A (en) * 1988-04-26 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Method for treating acne
WO2005011667A1 (en) * 2003-07-30 2005-02-10 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoid components

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MADANI K A ET AL: "The in vitro metabolism of 13-cis-retinoic acid in a model sebaceous structure, the rat preputial gland.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY NOV 1985, vol. 85, no. 5, November 1985 (1985-11-01), pages 465 - 469, XP007902411, ISSN: 0022-202X *
O'BRIEN S C ET AL: "The Leeds revised acne grading system", JOURNAL OF DERMATOLOGICAL TREATMENT 1998 UNITED KINGDOM, vol. 9, no. 4, 1998, pages 215 - 220, XP009084495, ISSN: 0954-6634 *
ORFANOS C E ET AL: "ORAL RETINOIDS IN THE TREATMENT OF SEBORRHOEA AND ACNE", DERMATOLOGY, vol. 196, no. 1, 1998, pages 140 - 147, XP000886013, ISSN: 1018-8665 *
RIGOPOULOS D ET AL: "Comparison of topical retinoids in the treatment of acne", CLINICS IN DERMATOLOGY, J.B. LIPPINCOTT, PHILADELPHIA, PA, US, vol. 22, no. 5, September 2004 (2004-09-01), pages 408 - 411, XP004647112, ISSN: 0738-081X *
YANG Y ET AL: "Determination of plasma and brain levels of isotretinoin in mice following single oral dose by high-performance liquid chromatography", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 37, no. 1, 7 February 2005 (2005-02-07), pages 157 - 163, XP004990505, ISSN: 0731-7085 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11851438B2 (en) 2022-03-02 2023-12-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and methods for treatment of viral infections

Also Published As

Publication number Publication date
EP1971331A2 (en) 2008-09-24
JP5112328B2 (en) 2013-01-09
JP2009518318A (en) 2009-05-07
US20090149536A1 (en) 2009-06-11
WO2007065289A2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2007065289A3 (en) 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
WO2008070116A3 (en) Topical compositions for treatment of skin conditions
PL378932A1 (en) Topical formulation of ivermectin for the treatment of dermatological conditions
WO2007129270A3 (en) Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle
WO2007096601A3 (en) Antimicrobial formulations comprising a quinone and a copper salt
WO2004037201A3 (en) Topical skin care composition
ZA200507346B (en) Topical formulation of ivermectin for the treatment of dermatological conditions
WO2004021968A3 (en) Solution for ungual application
WO2006107825A3 (en) Skin enrichment using coq10 as the delivery system
WO2008139122A3 (en) Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
EA200801717A1 (en) LOCAL APPLICATION COMPOSITION FOR SKIN CARE, PRODUCT ON ITS BASIS AND METHOD OF TREATMENT
AU2002368364A1 (en) Instrument for cryogenic treatments in the medical, paramedical and cosmetic field
AU2003265225A1 (en) Preparations for topical skin use and treatment
WO2007029187A3 (en) Use of protoberberines as an active substance regulating the pilosebaceous unit
WO2006087759A3 (en) Pharmaceutical composition comprising curcumin and resveratrol and uses thereof in medical field
EP2144608A4 (en) SOLAR SCREEN COMPOSITIONS AND METHODS
JO2434B1 (en) New Retinoids for the Treatment of Emphysema
WO2006102439A3 (en) Treatment or prevention of cancer and precancerous disorders
WO2003005980A3 (en) Cosmetic and dermatological preparations containing carnitine
WO2001062208A3 (en) Topical cosmetic agents containing 2-hydrazino-1,3-heteroazoles
AU2001250933A1 (en) Chitosan formulation with azelaic acid and other actives for the treatment of acne
WO2008050157A3 (en) Ozonated oil formulations
BRPI0914462A2 (en) "topical composition, method of preventing or reducing the occurrence of acne treatment and use of a composition"
AU2002366530A1 (en) Utilization of dihydropinosylvin and derivatives thereof as tyrosinase inhibitors for skin lightening or as antimicrobial substances for preservation or for the treatment of acne, dandruff or body odors
WO2005058230A3 (en) Topical use of halosalicylic acid derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008543631

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006817741

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006817741

Country of ref document: EP